Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.

ABSTRACT:

Background

Single-institution studies have shown the oncologic benefit of ablative liver radiotherapy (A-RT) for patients with unresectable intrahepatic cholangiocarcinoma (ICC). However, adoption of A-RT across the United States and its associated outcomes are unknown.

Methods

We queried the National Cancer Data Base for nonsurgically managed patients with ICC diagnosed between 2004 and 2018. Patients were labeled A-RT for receipt of biologically effective doses (BED₁₀ ) ≥ 80.5 Gy and conventional RT (Conv-RT) for lower doses. Associations with A-RT use and overall survival were identified using logistic and Cox regressions, respectively.

Results

Of 27,571 patients, the most common treatments were chemotherapy without liver RT (45%), no chemotherapy or liv

SUBMITTER: De B 

PROVIDER: S-EPMC9177808 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature